GO Main Menu Go Main Contents Go Bottom Menu
  • Vegzelma® image
    • Product Name : Vegzelma®
    • INN : bevacizumab
    • Indications : Metastatic carcinoma of the colon or rectum, Metastatic breast cancer, Non-small cell lung cancer, Advanced and/or metastatic renal cell cancer, Epithelial ovarian/fallopian tube and primary peritoneal cancer, Cervical cancer (*based on Vegzelma-SmPC)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : Bevacizumab binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells.
    • Drug Approval Status : USA, Europe, Japan, Korea, etc.

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.